Psychotropic medications selectively reshape the human gut microbiota and alter neuroactive metabolite production
Year: 2026
Type: preprint
Abstract: Psychotropic medications are widely prescribed and increasingly recognised to alter the gut microbiome. However, the mechanisms underlying these drug-microbiome interactions and their consequences for neuroactive microbial metabolism remain poorly understood. Here, we investigated the impact of commonly prescribed antidepressants and antipsychotics on gut microbiomes ex vivo. Among the drugs tested, sertraline and aripiprazole had the strongest effects on the gut microbiome, reducing overall microbial loads and altering the abundance of approximately 21% and 11% of microbial functional pathways, respectively. Both drugs also substantially remodelled microbial metabolism, affecting the production of microbial metabolites implicated in gut-brain signalling. Sertraline and aripiprazole both reduced indole levels, but the drugs had opposing effects on short-chain fatty acid production, which decreased with sertraline and increased with aripiprazole. Transcriptomic analyses of sertraline-exposed microbial cells revealed widespread disruption of membrane-associated transport and energy metabolism, with microscopy further supporting membrane dysfunction. By contrast, tametraline, a non-chlorinated and less lipophilic structural analogue of sertraline, produced negligible transcriptomic and microbiome-level effects. Together, our findings identify sertraline’s dichlorophenyl moiety and high lipophilicity as key determinants of microbial membrane dysfunction, establishing a mechanistic link between drug chemical structure, microbiome toxicity, and metabolic remodelling.
Source: Research Square
Institution: University of Southampton
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7233982285
